STRATA Skin Sciences Announces Independent Study Published in the Journal of The European Academy of Dermatology and Venereol...
March 15 2021 - 8:00AM
(NASDAQ: SSKN) STRATA Skin Sciences, Inc. (“STRATA”), a medical
technology company in Dermatology and Plastic Surgery dedicated to
developing, commercializing and marketing innovative products for
the treatment of dermatologic conditions, today announced the
publication of an independent study on the treatment of vitiligo
using the Company’s XTRAC excimer laser. The study was conducted by
a team of dermatologists in Japan and was approved by the Ethics
Committee of Kansai Medical University Kori Hospital. The results
of the study were published in the November 2020 issue of the
Journal of The European Academy of Dermatology and Venereology.
The study results demonstrated that patients
with refractory vitiligo achieved satisfactory repigmentation in
five treatments, including those who were previously unresponsive
to conventional treatments such as topical steroids, excimer light
and narrowband UVB light. These patients were treated under a
minimal blistering dose protocol using the XTRAC excimer laser,
which provided better therapeutic effects with fewer treatments as
compared to other UVB phototherapies. The study attributed better
patient outcomes to XTRAC’s higher irradiation rate as compared to
other available UVB phototherapies. In addition, the XTRAC
treatments were well tolerated, and the use of a minimal blistering
dose was shown to potentially reduce the number of treatment
sessions required, thereby lessening the burden on patients and
medical staff.
“We are delighted to see independent studies
performed that continue to validate and highlight the efficacy of
our XTRAC excimer laser in treating dermatologic diseases,” said
Bob Moccia, President and Chief Executive Officer. “There is a
large unmet need in Japan for the treatment of vitiligo, a
devastating condition with limited treatment options. As we
continue our focus on delivering our therapy solution to patients
in Japan, we are encouraged by the positive results of this study
to support our efforts; the data clearly demonstrate improved
clinical outcomes with XTRAC treatments over the alternatives to
treat vitiligo.”
Reference - Noborio, R., Nomura, Y., Nakamura,
M., Nishida, E., Kiyohara, T., Tanizaki, H. and Morita, A. (2021),
Efficacy of 308‐nm excimer laser treatment for refractory vitiligo:
a case series of treatment based on the minimal blistering dose. J
Eur Acad Dermatol Venereol.
About STRATA Skin Sciences,
Inc. (www.strataskinsciences.com)STRATA Skin Sciences is a
medical technology company in Dermatology and Plastic Surgery
dedicated to developing, commercializing and marketing innovative
products for the treatment of dermatologic conditions. Its products
include the XTRAC® excimer laser and VTRAC® lamp systems utilized
in the treatment of psoriasis, vitiligo and various other skin
conditions.
The Company’s proprietary XTRAC® excimer laser
delivers a highly targeted therapeutic beam of UVB light to treat
psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma,
diseases which impact over 31 million patients in the United States
alone. The technology is covered by multiple patents, including
exclusive rights for patents for the delivery of treatment to
vitiligo patients.
STRATA’s unique business model leverages
targeted Direct to Consumer (DTC) advertising to generate awareness
and utilizes its in-house call center and insurance advocacy teams
to increase volume for the Company’s partner dermatology
clinics.
The XTRAC business has used this proven DTC
model to grow its domestic dermatology partner network to over 832
clinics, with a worldwide installed base of over 2,300 devices. The
Company is able to offer 90% of DTC patients an introduction to
physicians prescribing a reimbursable solution, using XTRAC, within
a 10-mile radius of their house. The Company is a leader in
dermatology in-clinic business generation for its partners.
The Company has now introduced its Home by
XTRAC™ business, leveraging in-house resources; including DTC
advertising, in-house call center and its insurance reimbursement
team to provide an at-home, insurance-reimbursed treatment option
for patients with certain skin diseases that do not qualify for
in-office treatments.
Safe HarborThis press release
includes “forward-looking statements” within the meaning of the
Securities Litigation Reform Act of 1995. These statements include
but are not limited to the Company’s plans, objectives,
expectations and intentions and may contain words such as “will,”
“may,” “seeks,” and “expects,” that suggest future events or
trends. These statements, the Company’s ability to generate the
growth in its core business, the Company’s ability to develop
social media marketing campaigns, and the Company’s ability to
build a leading franchise in dermatology and aesthetics, the
Company’s ability to develop a business for home-based treatment of
skin diseases, are based on the Company’s current expectations and
are inherently subject to significant uncertainties and changes in
circumstances. Actual results may differ materially from the
Company’s expectations due to financial, economic, business,
competitive, market, regulatory, adverse market conditions or
supply chain interruptions resulting from the corona virus and
political factors or conditions affecting the Company and the
medical device industry in general, future responses to and effects
of COVID-19 pandemic, as well as more specific risks and
uncertainties set forth in the Company’s SEC reports on
Forms 10-Q and 10-K. Given such uncertainties, any or all these
forward-looking statements may prove to be incorrect or unreliable.
The statements in this press release are made as of the date of
this press release, even if subsequently made available by the
Company on its website or otherwise. The Company does not undertake
any obligation to update or revise these statements to reflect
events or circumstances occurring after the date of this press
release. The Company urges investors to carefully review its SEC
disclosures available at www.sec.gov and
www.strataskinsciences.com.
Investor Contacts:
Leigh Salvo |
|
|
(415) 937-5404 |
|
|
ir@strataskin.com |
|
|
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2023 to Apr 2024